Related Experiment Video
Updated: Jul 18, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.5K
Adjuvant Chemotherapy Is Associated With Prolonged Survival Time in Small-Breed Dogs Undergoing Amputation for
Stefano Zanardi1, Silvia Sabattini1, Federica Rossi2
1Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Bologna, Italy.
Veterinary and Comparative Oncology
|January 11, 2025
Summary
Adjuvant chemotherapy may improve survival for small-breed dogs with appendicular osteosarcoma. This study suggests chemotherapy benefits small dogs, but more research is needed to confirm its effectiveness against metastatic spread.
Area of Science:
- Veterinary Oncology
- Canine Cancer Research
- Surgical Oncology
Background:
- Adjuvant chemotherapy is standard for large-breed dogs with appendicular osteosarcoma.
- Its benefit in small-breed dogs remains understudied.
- Osteosarcoma is an aggressive bone cancer in dogs.
Purpose of the Study:
- To evaluate oncologic outcomes in small-breed dogs (<15kg) with appendicular osteosarcoma.
- To compare outcomes between dogs treated with surgery alone versus surgery plus adjuvant chemotherapy.
- To assess time to distant progression (TTDP) and overall survival (OS).
Main Methods:
- Retrospective review of medical records from multiple institutions.
- Analysis of 43 small-breed dogs with appendicular osteosarcoma.
- Comparison of outcomes based on surgical treatment with or without adjuvant chemotherapy.
Main Results:
- Median TTDP was 265 days, with no significant difference between groups.
- Median OS was 270 days.
- Dogs receiving adjuvant chemotherapy had significantly longer OS (353 days) compared to surgery alone (150 days).
Conclusions:
- Osteosarcoma in small breeds is as aggressive as in large breeds.
- Adjuvant chemotherapy may prolong survival in small-breed dogs.
- Further randomized trials are necessary to confirm the necessity of adjuvant chemotherapy for managing metastatic disease in this population.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...